Hsueh Yu-Mei, Chung Chi-Jung, Shiue Horng-Sheng, Chen Jin-Bor, Chiang Shou-Shan, Yang Mo-Hsiung, Tai Cheng-Wei, Su Chien-Tien
Department of Public Health, School of Medicine, Chang Gung Memorial Hospital, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Am J Kidney Dis. 2009 Nov;54(5):859-70. doi: 10.1053/j.ajkd.2009.06.016. Epub 2009 Aug 14.
Inorganic arsenic has been linked to decreased kidney function through oxidative damage. Arsenic methylation is believed to be a pathway for arsenic metabolism. Lycopene is an antioxidant that reduces oxidative stress; however, the association between urinary arsenic species, plasma lycopene level, and chronic kidney disease (CKD) has seldom been evaluated.
Case-control study.
SETTING & PARTICIPANTS: 125 patients with CKD and 229 controls were recruited from a hospital-based pool.
Urinary arsenic species and plasma lycopene level.
OUTCOMES & MEASUREMENTS: CKD was defined as estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m(2), calculated by using the Modification of Diet in Renal Disease Study equation. Plasma lycopene was measured by means of high-performance liquid chromatography. Urinary arsenic species, including arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, were determined by means of high-performance liquid chromatography and hydride generator-atomic absorption spectrometry.
Lycopene level was associated positively with eGFR, and participants with a high serum lycopene level had a significant, inverse association with CKD (odds ratio, 0.41; 95% confidence interval, 0.21 to 0.81). Total arsenic level was associated significantly with CKD in a dose-response relationship, especially in participants with a total arsenic level greater than 20.74 compared with 11.78 microg/g creatinine or less (odds ratio, 4.34; 95% confidence interval, 1.94 to 9.69). Furthermore, participants with a high urinary total arsenic level or participants with a low percentage of dimethylarsinic acid had a positive association with CKD when their plasma lycopene level was low.
Because of the single spot evaluation of plasma antioxidants and urinary arsenic species and the small sample size, statistical significance should be interpreted with caution.
This study shows that high urinary total arsenic or low plasma lycopene level is associated positively with CKD. Results suggest that the capacity for arsenic methylation may be associated with CKD in individuals who ingest low arsenic levels in drinking water and also have a low plasma lycopene level.
无机砷通过氧化损伤与肾功能下降有关。砷甲基化被认为是砷代谢的一条途径。番茄红素是一种能减轻氧化应激的抗氧化剂;然而,尿砷形态、血浆番茄红素水平与慢性肾脏病(CKD)之间的关联很少被评估。
病例对照研究。
从一个基于医院的人群中招募了125例CKD患者和229名对照。
尿砷形态和血浆番茄红素水平。
CKD定义为使用肾脏病膳食改良研究方程计算的估计肾小球滤过率(eGFR)低于60 mL/(min·1.73 m²)。血浆番茄红素通过高效液相色谱法测量。尿砷形态,包括亚砷酸盐、砷酸盐、一甲基砷酸和二甲基砷酸,通过高效液相色谱法和氢化物发生-原子吸收光谱法测定。
番茄红素水平与eGFR呈正相关,血清番茄红素水平高的参与者与CKD呈显著负相关(比值比,0.41;95%置信区间,0.21至0.81)。总砷水平与CKD呈显著的剂量反应关系,尤其是总砷水平大于20.74的参与者与总砷水平小于或等于11.78 μg/g肌酐的参与者相比(比值比,4.34;95%置信区间,1.94至9.69)。此外,当血浆番茄红素水平低时,尿总砷水平高的参与者或二甲基砷酸百分比低的参与者与CKD呈正相关。
由于对血浆抗氧化剂和尿砷形态进行的是单点评估且样本量小,对统计显著性的解释应谨慎。
本研究表明,尿总砷水平高或血浆番茄红素水平低与CKD呈正相关。结果表明,在饮用水中砷摄入量低且血浆番茄红素水平也低的个体中,砷甲基化能力可能与CKD有关。